{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:33:38Z","timestamp":1787319218266,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03583-7","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:00:28Z","timestamp":1775725228000},"page":"2408-2420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-factor Therapies in Hemophilia: Mechanisms, Clinical Evidence, Patient Management, and Future Perspectives"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-2782","authenticated-orcid":false,"given":"Yuto","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"4","key":"3583_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5435\/00124635-200407000-00004","volume":"12","author":"JV Luck Jr","year":"2004","unstructured":"Luck JV Jr, Silva M, Rodriguez-Merchan EC, Ghalambor N, Zahiri CA, Finn RS. Hemophilic arthropathy. J Am Acad Orthop Surg. 2004;12(4):234\u201345.","journal-title":"J Am Acad Orthop Surg"},{"issue":"3","key":"3583_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1055\/s-0037-1615621","volume":"85","author":"GC White","year":"2001","unstructured":"White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, et al. Definitions in hemophilia. recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.","journal-title":"Thromb Haemost"},{"issue":"Suppl 6","key":"3583_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"3","key":"3583_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","volume":"123","author":"J Mahlangu","year":"2014","unstructured":"Mahlangu J, Powell JS, Ragni MV, A-LONG Investigators, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317\u201325.","journal-title":"Blood"},{"issue":"13","key":"3583_CR5","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","volume":"119","author":"JS Powell","year":"2012","unstructured":"Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in Hemophilia A patients. Blood. 2012;119(13):3031\u20137.","journal-title":"Blood"},{"issue":"4","key":"3583_CR6","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/jth.12161","volume":"11","author":"A Tiede","year":"2013","unstructured":"Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycol PEGylated recombinant factor VIII in patients with Hemophilia A. J Thromb Haemost. 2013;11(4):670\u20138.","journal-title":"J Thromb Haemost"},{"key":"3583_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2025.109306","volume":"249","author":"E Zanon","year":"2025","unstructured":"Zanon E, Porreca A, Napolitano A, Simion C, Simioni P. FVIII half-life products: a real-world experience. Thromb Res. 2025;249:109306.","journal-title":"Thromb Res"},{"issue":"1","key":"3583_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/j.seminhematol.2015.10.004","volume":"53","author":"D Angelini","year":"2016","unstructured":"Angelini D, Konkle BA, Sood SL. Aging among persons with hemophilia: contemporary concerns. Semin Hematol. 2016;53(1):35\u20139.","journal-title":"Semin Hematol"},{"issue":"1","key":"3583_CR9","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2020.001","volume":"12","author":"P Tieu","year":"2020","unstructured":"Tieu P, Chan A, Matino D. Molecular mechanisms of inhibitor development in hemophilia. Mediterr J Hematol Infect Dis. 2020;12(1):e2020001.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"Suppl 1","key":"3583_CR10","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1160\/TH16-01-0049","volume":"116","author":"CE Walsh","year":"2016","unstructured":"Walsh CE, Jim\u00e9nez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. Thromb Haemost. 2016;116(Suppl 1):S10\u20137.","journal-title":"Thromb Haemost"},{"issue":"1","key":"3583_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1365-2516.2006.01403.x","volume":"13","author":"J Astermark","year":"2007","unstructured":"Astermark J, Rocino A, Von Depka M, EHTSB, et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia. 2007;13(1):38\u201345.","journal-title":"Haemophilia"},{"issue":"4","key":"3583_CR12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1046\/j.1365-2516.2003.00781.x","volume":"9","author":"J Wight","year":"2003","unstructured":"Wight J, Paisley S, Knight C. Immune tolerance induction in patients with Haemophilia A with inhibitors: a systematic review. Haemophilia. 2003;9(4):436\u201363.","journal-title":"Haemophilia"},{"issue":"1","key":"3583_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2516.2008.01931.x","volume":"15","author":"E Berntorp","year":"2009","unstructured":"Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009;15(1):3\u201310.","journal-title":"Haemophilia"},{"issue":"5","key":"3583_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s12185-014-1572-4","volume":"99","author":"K Ogiwara","year":"2014","unstructured":"Ogiwara K, Nogami K, Matsumoto T, Shima M. Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe Hemophilia A patients with inhibitor. Int J Hematol. 2014;99(5):577\u201387.","journal-title":"Int J Hematol"},{"issue":"11","key":"3583_CR15","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1111\/j.1538-7836.2009.03615.x","volume":"7","author":"A Coppola","year":"2009","unstructured":"Coppola A, Margaglione M, Santagostino E, AICE PROFIT Study Group, et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost. 2009;7(11):1809\u201315.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3583_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1055\/s-0044-1796651","volume":"51","author":"V Jim\u00e9nez-Yuste","year":"2025","unstructured":"Jim\u00e9nez-Yuste V. Non-factor therapies for hemophilia: achievements and perspectives. Semin Thromb Hemost. 2025;51(1):23\u20137.","journal-title":"Semin Thromb Hemost"},{"issue":"21","key":"3583_CR17","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","volume":"374","author":"M Shima","year":"2016","unstructured":"Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044\u201353.","journal-title":"N Engl J Med"},{"issue":"9","key":"3583_CR18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809\u201318.","journal-title":"N Engl J Med"},{"issue":"2","key":"3583_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1161\/ATVBAHA.107.141606","volume":"28","author":"JT Crawley","year":"2008","unstructured":"Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2008;28(2):233\u201342.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"3583_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S1357-2725(03)00244-9","volume":"36","author":"NS Quinsey","year":"2004","unstructured":"Quinsey NS, Greedy AL, Bottomley SP, Whisstock JC, Pike RN. Antithrombin: in control of coagulation. Int J Biochem Cell Biol. 2004;36(3):386\u20139.","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"3583_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1365-2141.2007.06693.x","volume":"138","author":"S Shetty","year":"2007","unstructured":"Shetty S, Vora S, Kulkarni B, Mota L, Vijapurkar M, Quadros L, et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol. 2007;138(4):541\u20134.","journal-title":"Br J Haematol"},{"issue":"8","key":"3583_CR22","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.chembiol.2012.07.011","volume":"19","author":"GF Deleavey","year":"2012","unstructured":"Deleavey GF, Damha MJ. Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol. 2012;19(8):937\u201354.","journal-title":"Chem Biol"},{"issue":"24","key":"3583_CR23","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","volume":"134","author":"G Young","year":"2019","unstructured":"Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127\u201338.","journal-title":"Blood"},{"issue":"9","key":"3583_CR24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811\u201322.","journal-title":"N Engl J Med"},{"issue":"6","key":"3583_CR25","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","volume":"6","author":"SW Pipe","year":"2019","unstructured":"Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, nonrandomized phase 3 study. Lancet Haematol. 2019;6(6):e295\u2013305.","journal-title":"Lancet Haematol"},{"issue":"14","key":"3583_CR26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1182\/blood.2023021832","volume":"143","author":"SW Pipe","year":"2024","unstructured":"Pipe SW, Collins P, Dhalluin C, et al. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024;143(14):1355\u201364.","journal-title":"Blood"},{"issue":"2","key":"3583_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12670","volume":"6","author":"R Yang","year":"2022","unstructured":"Yang R, Wang S, Wang X, et al. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5). Res Pract Thromb Haemost. 2022;6(2):e12670.","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"3583_CR28","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","volume":"10","author":"C N\u00e9grier","year":"2023","unstructured":"N\u00e9grier C, Mahlangu J, Lehle M, et al. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open label, single-arm, phase 3 study. Lancet Haematol. 2023;10(3):e168\u201377.","journal-title":"Lancet Haematol"},{"issue":"3","key":"3583_CR29","doi-asserted-by":"publisher","first-page":"103849","DOI":"10.1016\/j.htct.2025.103849","volume":"47","author":"IO Araujo","year":"2025","unstructured":"Araujo IO, Suassuna LF, Dos Santos IL, Rodrigues DOW. Efficacy, safety and satisfaction of using emicizumab in hemophilia A patients without factor VIII inhibitors: a systematic review. Hematol Transfus Cell Ther. 2025;47(3):103849\u2013103849.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"4","key":"3583_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s12185-021-03276-7","volume":"115","author":"Y Nakajima","year":"2022","unstructured":"Nakajima Y, Mizumachi K, Shimonishi N, et al. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients. Int J Hematol. 2022;115(4):489\u201398.","journal-title":"Int J Hematol"},{"issue":"14","key":"3583_CR31","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood.2020010331","volume":"138","author":"H \u00d8stergaard","year":"2021","unstructured":"\u00d8stergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138(14):1258\u201368.","journal-title":"Blood"},{"issue":"6","key":"3583_CR32","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/jth.15682","volume":"20","author":"B Lauritzen","year":"2022","unstructured":"Lauritzen B, Bjelke M, Bjorkdahl O, et al. A novel next-generation FVIII mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: results from safety studies in cynomolgus monkeys. J Thromb Haemost. 2022;20(6):1312\u201324.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"3583_CR33","doi-asserted-by":"publisher","first-page":"102181","DOI":"10.1016\/j.rpth.2023.102181","volume":"7","author":"P Persson","year":"2023","unstructured":"Persson P, Amstrup AB, Coester HV, Matytsina I, Bas S. Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults. Res Pract Thromb Haemost. 2023;7(6):102181\u2013102181.","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"3583_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-137006","volume":"136","author":"B Lauritzen","year":"2020","unstructured":"Lauritzen B, Bjelke M, Rossen M, et al. A novel next-generation FVIII Mimetic, Mim8, has a favourable safety profile. Results from a 26-week safety study in cynomolgus monkeys. Blood. 2020;136(Suppl 1):26\u20137.","journal-title":"Blood"},{"issue":"4","key":"3583_CR35","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jtha.2023.12.016","volume":"22","author":"SR Lentz","year":"2024","unstructured":"Lentz SR, Chowdary P, Gil L, et al. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. J Thromb Haemost. 2024;22(4):990\u20131000.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"3583_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jtha.2023.09.034","volume":"22","author":"Y Teranishi-Ikawa","year":"2024","unstructured":"Teranishi-Ikawa Y, Soeda T, Koga H, et al. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state. J Thromb Haemost. 2024;22(2):430\u201340.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"3583_CR37","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1016\/j.jtha.2025.03.034","volume":"23","author":"K Ogiwara","year":"2025","unstructured":"Ogiwara K, Furukawa S, Inaba K, et al. Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A. J Thromb Haemost. 2025;23(7):2164\u201377.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"3583_CR38","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/jth.12864","volume":"13","author":"P Chowdary","year":"2015","unstructured":"Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743\u201354.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"3583_CR39","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1111\/jth.14272","volume":"16","author":"H Eichler","year":"2018","unstructured":"Eichler H, Angchaisuksiri P, Kavakli K, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of Concizumab in people with hemophilia A. J Thromb Haemost. 2018;16(11):2184\u201395.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"3583_CR40","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1182\/bloodadvances.2021006403","volume":"6","author":"AD Shapiro","year":"2022","unstructured":"Shapiro AD, Angchaisuksiri P, Astermark J, et al. Long-term efficacy and safety of subcutaneous Concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors. Blood Adv. 2022;6(11):3422\u201332.","journal-title":"Blood Adv"},{"issue":"9","key":"3583_CR41","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2216455","volume":"389","author":"T Matsushita","year":"2023","unstructured":"Matsushita T, Shapiro A, Abraham A, explorer7 Investigators, et al. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023;389(9):783\u201394.","journal-title":"N Engl J Med"},{"issue":"2","key":"3583_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.102705","volume":"9","author":"P Angchaisuksiri","year":"2025","unstructured":"Angchaisuksiri P, von Mackensen S, Apte S, et al. Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study. Res Pract Thromb Haemost. 2025;9(2):102705.","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"3583_CR43","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.xphs.2018.03.010","volume":"107","author":"C Parng","year":"2018","unstructured":"Parng C, Singh P, Pittman DD, et al. Translational pharmacokinetic\/pharmacodynamic characterization and target-mediated drug disposition modeling of an anti-Tissue Factor Pathway Inhibitor antibody, PF-06741086. J Pharm Sci. 2018;107(7):1995\u20132004.","journal-title":"J Pharm Sci"},{"issue":"2","key":"3583_CR44","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/bjh.18420","volume":"200","author":"JN Mahlangu","year":"2023","unstructured":"Mahlangu JN, Lamas JL, Morales JC, et al. A phase 1b\/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol. 2023;200(2):229\u201339.","journal-title":"Br J Haematol"},{"issue":"2","key":"3583_CR45","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.18495","volume":"200","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, Luis Lamas J, Cristobal Morales J, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol. 2023;200(2):240\u20138.","journal-title":"Br J Haematol"},{"issue":"14","key":"3583_CR46","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood.2024027468","volume":"146","author":"D Matino","year":"2025","unstructured":"Matino D, Palladino A, Taylor CT, et al. Marstacimab prophylaxis in hemophilia A\/B without inhibitors: results from the phase 3 BASIS trial. Blood. 2025;146(14):1654\u201363.","journal-title":"Blood"},{"issue":"5","key":"3583_CR47","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm.3847","volume":"21","author":"A Sehgal","year":"2015","unstructured":"Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21(5):492\u20137.","journal-title":"Nat Med"},{"issue":"9","key":"3583_CR48","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1616569","volume":"377","author":"KJ Pasi","year":"2017","unstructured":"Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377(9):819\u201328.","journal-title":"N Engl J Med"},{"issue":"6","key":"3583_CR49","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/jth.15270","volume":"19","author":"KJ Pasi","year":"2021","unstructured":"Pasi KJ, Lissitchkov T, Mamonov V, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran\u2013results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021;19(6):1436\u201346.","journal-title":"J Thromb Haemost"},{"issue":"10386","key":"3583_CR50","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","volume":"401","author":"G Young","year":"2023","unstructured":"Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet. 2023;401(10386):1427\u201337.","journal-title":"Lancet"},{"issue":"5","key":"3583_CR51","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","volume":"10","author":"A Srivastava","year":"2023","unstructured":"Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open label, randomised, phase 3 trial. Lancet Haematol. 2023;10(5):e322\u201332.","journal-title":"Lancet Haematol"},{"issue":"22","key":"3583_CR52","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1182\/blood.2023021864","volume":"143","author":"G Kenet","year":"2024","unstructured":"Kenet G, Nolan B, Zulfikar B, et al. Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis: the ATLAS-PPX trial. Blood. 2024;143(22):2256\u201369.","journal-title":"Blood"},{"key":"3583_CR53","doi-asserted-by":"crossref","unstructured":"Baglin T, Huntington JA, Koch A, Mocanu I, Makhaldiani L. Serpin-PC in persons with severe hemophilia (PwH): updated results from a multicenter multi-part, first-in-human study. Paper presented at: ASH Meeting 2023; December 10, 2023.","DOI":"10.1182\/blood-2023-179969"},{"key":"3583_CR54","unstructured":"World Federation of Hemophilia. WFH statement on recent developments related to hemophilia therapies. 2025. https:\/\/wfh.org\/article\/wfh-statement-on-recent-developments-related-to-hemophilia-therapies\/. Accessed 2026 Mar 3"},{"issue":"Suppl 1","key":"3583_CR55","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2022-170245","volume":"140","author":"L Leong","year":"2022","unstructured":"Leong L, Byun T, Kim B, Huck I. Pre-clinical characterization of VGA039, an anti-protein S monoclonal antibody being developed as a universal hemostatic agent for various bleeding disorders. Blood. 2022;140(Suppl 1):1666\u20137.","journal-title":"Blood"},{"issue":"2","key":"3583_CR56","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/rth2.12295","volume":"4","author":"S Aghighi","year":"2019","unstructured":"Aghighi S, Riddell A, Lee CA, Brown SA, Tuddenham E, Chowdary P. Global coagulation assays in hemophilia A: a comparison to conventional assays. Res Pract Thromb Haemost. 2019;4(2):298\u2013308.","journal-title":"Res Pract Thromb Haemost"},{"key":"3583_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/hae.70203","author":"H Eichler","year":"2026","unstructured":"Eichler H, Butta NV, Riddell A, et al. Investigation of the suitability of the ROTEM assay to measure coagulation potential in blood from patients on Concizumab prophylaxis. Haemophilia. 2026. https:\/\/doi.org\/10.1111\/hae.70203.","journal-title":"Haemophilia"},{"issue":"4","key":"3583_CR58","first-page":"711","volume":"11","author":"SS Chiou","year":"2024","unstructured":"Chiou SS, Lin CY, Weng TF, Taiwan Society of Thrombosis, Hemostasis (TSTH) Study Group, et al. Evaluating the effectiveness of prophylactic strategies for hemophilia A management: a real-world, longitudinal observational study. Drugs. 2024;11(4):711\u201323.","journal-title":"Drugs"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03583-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03583-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03583-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:03:03Z","timestamp":1780120983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03583-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3583"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03583-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yuto Nakajima received grants from Takeda Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., and KM Biologics Co., Ltd. Keiji Nogami received grants, personal fees, and non-financial support from Chugai Pharmaceutical Co., Ltd.; personal fees from F. Hoffmann-La Roche Ltd.; grants and personal fees from Sysmex Co., SEKISUI MEDICAL, Takeda Pharmaceutical Co., Sanofi S.A., CSL Behring Co., KM Biologics Co., Novo Nordisk A\/S, Bayer AG, Pfizer Inc., and Fujimoto Pharmaceutical Co..","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}